Why the study?
Does prophylactic bronchial artery infusion with anticancer agents improve 5-year survival in patients with osteosarcoma of the limb without pulmonary metastasis?
Does prophylactic bronchial artery infusion with anticancer agents improve 5-year survival in patients with osteosarcoma of the limb without pulmonary metastasis?
Prophylactic bronchial artery infusion of anticancer agents in osteosarcoma patients without pulmonary metastasis resulted in a 36.7% 5-year survival rate, which the authors considered encouraging compared to previous regimens.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in limb osteosarcoma without pulmonary metastasis; hypothesis-generating and requires randomized confirmation.
Since March 1965, we have performed prophylactic infusions of the lung with anticancer agents via the bronchial arteries using a Mahajan-Cliffton triple lumen, double balloon catheter in order to prevent pulmonary metastasis of osteosarcoma and to improve its prognosis. Prior to March 1970, we performed this procedure on 82 occasions for 35 patients with the malignancy of the limb who were found to have had no pulmonary metastasis on chest roent-genogram at the time of the first infusion. The percentage of patients surviving 5 years by life-table technique was 36.7%, of which the standard error was 9.9%. Complications following this procedure were observed in detail. All of the complications were negligible considering the usual poor prognosis of osteosarcoma. These results are very encouraging when compared with those obtained by our previous therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
Tohgo Ohno (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: